GleamWall
中文EN

CVM CEL SCI CORP

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 725363 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.9%
TTM EPS YoY81.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-252.5%
ROA-108.9%
ROIC (approx.)-364.5%
Asset turnover—

Leverage & solvency

Liabilities / assets48.7%
Debt / equity0.00x
Current ratio1.48x
Interest coverage-50.08x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-28.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue————————
R&D expense$3.65M$3.77M$3.68M$3.70M$3.74M$4.01M$4.43M$4.48M
SG&A expense$1.91M$1.56M$1.69M$2.33M$1.75M$2.38M$2.46M$1.64M
Operating income-$5.56M-$5.33M-$5.37M-$6.03M-$5.49M-$6.39M-$6.89M-$6.12M
Interest expense$111,000$117,000$88,000$129,000$172,000$178,000$170,000—
Net income-$5.67M-$5.47M-$5.47M-$6.10M-$5.66M-$6.57M-$7.07M-$6.77M
EBITDA-$4.61M-$4.37M-$4.40M-$6.90M-$4.53M-$5.42M-$5.90M-$6.96M
EPS (diluted)-0.47-0.67-0.68—-1.36-2.33-3.25—
Weighted avg. shares (diluted)12.12M8.14M8.02M—4.15M2.82M2.18M—
Banking
Net interest income-$110,240-$117,485-$87,789-$128,505-$172,050-$178,286-$170,103-$174,571
Balance sheet
Cash & equivalents$6.53M$1.89M$6.28M$10.95M$1.79M$1.92M$4.61M$4.74M
Inventory———————$1.02M
Current assets$7.50M$2.89M$7.03M$11.60M$2.62M$3.02M$5.86M$6.06M
PP&E, net$4.58M$5.07M$5.57M$6.08M$6.58M$7.08M$7.59M$8.13M
Intangibles$69,688$73,328$101,548$119,856$130,585$141,263$148,394$165,492
Total assets$21.36M$17.71M$22.89M$28.16M$20.34M$21.81M$25.70M$26.99M
Current liabilities$5.08M$4.81M$5.04M$5.13M$5.62M$5.50M$5.48M$4.62M
Short-term debt———$2.27M————
Long-term debt———$5.68M————
Total debt———$7.96M————
Total liabilities$10.40M$10.83M$11.76M$12.20M$13.31M$13.81M$14.39M$14.12M
Shareholders' equity$10.96M$6.87M$11.14M$15.96M$7.02M$8.00M$11.31M$12.87M
Net debt———-$3.00M————
Shares outstanding17.59M8.49M8.42M8.02M5.32M84.35M74.08M2.13M
Cash flow statement
Operating cash flow-$4.03M-$4.02M-$4.02M-$4.67M-$3.94M-$4.37M-$4.14M-$4.82M
Capital expenditure$0$0$0$5,155$0$0$32,954$19,753
Free cash flow-$4.03M-$4.02M-$4.02M-$4.68M-$3.94M-$4.37M-$4.17M-$4.84M
Investing cash flow$0$0$0-$5,155$0$0-$32,954-$19,753
Financing cash flow$8.67M-$364,461-$653,773$13.84M$3.81M$1.68M$4.05M$9.19M
Depreciation & amortization$946,370$956,401$964,422-$868,303$959,009$970,102$995,192-$842,603
Stock-based compensation$454,094$451,381$443,275$440,506$73,441$685,669$711,381$725,611

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.